Literature DB >> 22983507

Clinical variability of family members with the C104R mutation in transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI).

Wikke Koopmans1, See-Tarn Woon, Anna E S Brooks, P Rod Dunbar, Peter Browett, Rohan Ameratunga.   

Abstract

PURPOSE: Common Variable Immunodeficiency Disorder (CVID) is a complex disorder that predisposes patients to recurrent and severe infections. The C104R mutation in the transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI) is the most frequent mutation identified in patients with CVID. We carried out a detailed immunological and molecular study in a family with a C104R mutation.
METHODS: We have undertaken segregation analysis of a kindred with C104R mutations of the TACI gene. Detailed immunological and molecular investigations were carried out for this kindred and the clinical phenotype was compared to the genotype.
RESULTS: Segregation analysis of our kindred showed that inheriting single or double copy of the C104R mutation does not consign an individual to CVID. All heterozygotes in the family were phenotypically different, ranging from asymptomatic to ill-health. A family member with a wild type TACI variant had CVID-related phenotype including IgA deficiency and type 1 diabetes. Interestingly, a family member with the homozygous C104R/C104R variant did not meet the criteria for CVID because he had excellent, albeit unsustained, vaccine responses to T cell dependent and T cell independent vaccine antigens despite profound hypogammaglobulinemia.
CONCLUSION: The C104R mutation does not correlate with the clinical phenotypes in this family.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22983507     DOI: 10.1007/s10875-012-9793-x

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  35 in total

1.  The immunogenicity of Haemophilus influenzae: meningococcal protein conjugate vaccine in Polynesian and non-Polynesian New Zealand infants.

Authors:  S N Ameratunga; D R Lennon; B Entwistle; E Robinson; R V Ameratunga
Journal:  J Paediatr Child Health       Date:  1997-04       Impact factor: 1.954

2.  CD81 gene defect in humans disrupts CD19 complex formation and leads to antibody deficiency.

Authors:  Menno C van Zelm; Julie Smet; Brigitte Adams; Françoise Mascart; Liliane Schandené; Françoise Janssen; Alina Ferster; Chiung-Chi Kuo; Shoshana Levy; Jacques J M van Dongen; Mirjam van der Burg
Journal:  J Clin Invest       Date:  2010-03-08       Impact factor: 14.808

3.  The simultaneous presentation of sarcoidosis and common variable immune deficiency.

Authors:  R Ameratunga; D M Becroft; W Hunter
Journal:  Pathology       Date:  2000-11       Impact factor: 5.306

4.  An antibody-deficiency syndrome due to mutations in the CD19 gene.

Authors:  Menno C van Zelm; Ismail Reisli; Mirjam van der Burg; Diana Castaño; Carel J M van Noesel; Maarten J D van Tol; Cristina Woellner; Bodo Grimbacher; Pablo J Patiño; Jacques J M van Dongen; José L Franco
Journal:  N Engl J Med       Date:  2006-05-04       Impact factor: 91.245

5.  TNFRSF13B/TACI alterations in Greek patients with antibody deficiencies.

Authors:  Matthaios Speletas; Antigoni Mamara; Efimia Papadopoulou-Alataki; George Iordanakis; Kyriaki Liadaki; Fotini Bardaka; Maria Kanariou; Anastasios E Germenis
Journal:  J Clin Immunol       Date:  2011-05-06       Impact factor: 8.317

6.  Diagnostic criteria for primary immunodeficiencies. Representing PAGID (Pan-American Group for Immunodeficiency) and ESID (European Society for Immunodeficiencies).

Authors:  M E Conley; L D Notarangelo; A Etzioni
Journal:  Clin Immunol       Date:  1999-12       Impact factor: 3.969

7.  Major histocompatibility complex class III genes and susceptibility to immunoglobulin A deficiency and common variable immunodeficiency.

Authors:  J E Volanakis; Z B Zhu; F M Schaffer; K J Macon; J Palermos; B O Barger; R Go; R D Campbell; H W Schroeder; M D Cooper
Journal:  J Clin Invest       Date:  1992-06       Impact factor: 14.808

8.  TACI mutations and disease susceptibility in patients with common variable immunodeficiency.

Authors:  A E J Poodt; G J A Driessen; A de Klein; J J M van Dongen; M van der Burg; E de Vries
Journal:  Clin Exp Immunol       Date:  2008-12-11       Impact factor: 4.330

9.  Shared HLA class II-associated genetic susceptibility and resistance, related to the HLA-DQB1 gene, in IgA deficiency and common variable immunodeficiency.

Authors:  O Olerup; C I Smith; J Björkander; L Hammarström
Journal:  Proc Natl Acad Sci U S A       Date:  1992-11-15       Impact factor: 11.205

Review 10.  Translational mini-review series on immunodeficiency: molecular defects in common variable immunodeficiency.

Authors:  C Bacchelli; S Buckridge; A J Thrasher; H B Gaspar
Journal:  Clin Exp Immunol       Date:  2007-09       Impact factor: 4.330

View more
  12 in total

1.  Profound Reversible Hypogammaglobulinemia Caused by Celiac Disease in the Absence of Protein Losing Enteropathy.

Authors:  Rohan Ameratunga; Russell William Barker; Richard Henderson Steele; Maneka Deo; See-Tarn Woon; Mee Ling Yeong; Wikke Koopmans
Journal:  J Clin Immunol       Date:  2015-08-29       Impact factor: 8.317

Review 2.  Review: Diagnosing Common Variable Immunodeficiency Disorder in the Era of Genome Sequencing.

Authors:  Rohan Ameratunga; Klaus Lehnert; See-Tarn Woon; David Gillis; Vanessa L Bryant; Charlotte A Slade; Richard Steele
Journal:  Clin Rev Allergy Immunol       Date:  2018-04       Impact factor: 8.667

3.  TACI deficiency enhances antibody avidity and clearance of an intestinal pathogen.

Authors:  Shoichiro Tsuji; Lucas Stein; Nobuhiko Kamada; Gabriel Nuñez; Richard Bram; Bruce A Vallance; Ana E Sousa; Jeffrey L Platt; Marilia Cascalho
Journal:  J Clin Invest       Date:  2014-10-01       Impact factor: 14.808

Review 4.  New diagnostic criteria for common variable immune deficiency (CVID), which may assist with decisions to treat with intravenous or subcutaneous immunoglobulin.

Authors:  R Ameratunga; S-T Woon; D Gillis; W Koopmans; R Steele
Journal:  Clin Exp Immunol       Date:  2013-11       Impact factor: 4.330

5.  Comprehensive genetic testing for primary immunodeficiency disorders in a tertiary hospital: 10-year experience in Auckland, New Zealand.

Authors:  See-Tarn Woon; Rohan Ameratunga
Journal:  Allergy Asthma Clin Immunol       Date:  2016-12-07       Impact factor: 3.406

6.  Clinical Implications of Digenic Inheritance and Epistasis in Primary Immunodeficiency Disorders.

Authors:  Rohan Ameratunga; See-Tarn Woon; Vanessa L Bryant; Richard Steele; Charlotte Slade; Euphemia Yee Leung; Klaus Lehnert
Journal:  Front Immunol       Date:  2018-01-26       Impact factor: 7.561

7.  Hypogammaglobulinemia factitia- Munchausen syndrome masquerading as common variable immune deficiency.

Authors:  Rohan Ameratunga; Paul Casey; Susan Parry; Chris Kenedi
Journal:  Allergy Asthma Clin Immunol       Date:  2013-09-17       Impact factor: 3.406

Review 8.  Comparison of diagnostic criteria for common variable immunodeficiency disorder.

Authors:  Rohan Ameratunga; Maia Brewerton; Charlotte Slade; Anthony Jordan; David Gillis; Richard Steele; Wikke Koopmans; See-Tarn Woon
Journal:  Front Immunol       Date:  2014-09-15       Impact factor: 7.561

9.  Evaluating the Genetics of Common Variable Immunodeficiency: Monogenetic Model and Beyond.

Authors:  Guillem de Valles-Ibáñez; Ana Esteve-Solé; Mònica Piquer; E Azucena González-Navarro; Jessica Hernandez-Rodriguez; Hafid Laayouni; Eva González-Roca; Ana María Plaza-Martin; Ángela Deyà-Martínez; Andrea Martín-Nalda; Mónica Martínez-Gallo; Marina García-Prat; Lucía Del Pino-Molina; Ivón Cuscó; Marta Codina-Solà; Laura Batlle-Masó; Manuel Solís-Moruno; Tomàs Marquès-Bonet; Elena Bosch; Eduardo López-Granados; Juan Ignacio Aróstegui; Pere Soler-Palacín; Roger Colobran; Jordi Yagüe; Laia Alsina; Manel Juan; Ferran Casals
Journal:  Front Immunol       Date:  2018-05-14       Impact factor: 7.561

10.  Epistatic interactions between mutations of TACI (TNFRSF13B) and TCF3 result in a severe primary immunodeficiency disorder and systemic lupus erythematosus.

Authors:  Rohan Ameratunga; Wikke Koopmans; See-Tarn Woon; Euphemia Leung; Klaus Lehnert; Charlotte A Slade; Jessica C Tempany; Anselm Enders; Richard Steele; Peter Browett; Philip D Hodgkin; Vanessa L Bryant
Journal:  Clin Transl Immunology       Date:  2017-10-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.